Concepedia

Dismal survival outcomes of patients with acute myeloid leukemia after failure of venetoclax with hypomethylating agents

Carl Zainaldin, Sankalp Arora, Srilakshmi Bathini, Udita Gupta, Vishruti Pandya, Sejong Bae, Sarah Worth, Kimo Bachiashvili, Ravi Bhatia, Kelly Godby,

Leukemia & lymphoma/Leukemia and lymphoma · 2022 · 11 citations · 7 references

DOI

Concepts

References

7

Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

Courtney D. DiNardo, Brian A. Jonas, Vinod Pullarkat et al. · New England Journal of Medicine · 2020 · 2.8K citations · Full text

, , +3

Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML

Courtney D. DiNardo, Ing Soo Tiong, Anna Quaglieri et al. · Blood · 2020 · 649 citations · Full text

, , +9

10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial

Courtney D. DiNardo, Abhishek Maiti, Caitlin R. Rausch et al. · The Lancet Haematology · 2020 · 331 citations · Full text

, , +16

Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia

Qi Zhang, Bridget Riley‐Gillis, Lina Han et al. · Signal Transduction and Targeted Therapy · 2022 · 181 citations · Full text

, , +17

Outcomes of Adults With Relapsed/Refractory Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents at a Comprehensive Cancer Center

Matthew E. Tenold, Benjamin Moskoff, David J. Benjamin et al. · Frontiers in Oncology · 2021 · 55 citations · Full text

, , +13